Affinage

LYL1

Protein lyl-1 · UniProt P12980

Length
280 aa
Mass
29.9 kDa
Annotated
2026-04-28
40 papers in source corpus 23 papers cited in narrative 23 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

LYL1 is a basic helix-loop-helix (bHLH) transcription factor that functions as a critical regulator of hematopoietic stem cell maintenance, multilineage blood cell differentiation, and vascular maturation. LYL1 heterodimerizes with E2A proteins (E12/E47) via its HLH domain to bind a preferred DNA consensus sequence (5'-AACAGATG(T/g)T-3'), and acts redundantly with SCL/TAL1 in adult HSC survival, primitive erythropoiesis, and megakaryopoiesis, while playing non-redundant roles in B-cell development, early T-cell progenitor maintenance (where it activates Gfi1), and endothelial barrier integrity through regulation of Rho GTPase-activating proteins (ARHGAP21/24), VE-cadherin junctional recruitment, and Rap1/RhoA signaling (PMID:8628307, PMID:19200805, PMID:30185409, PMID:31300405, PMID:22404772, PMID:24532287). LYL1 assembles into multiprotein transcriptional complexes with LMO2, GATA2, and LDB1 at E-box/GATA composite elements on target promoters, interacts with CREB1 to recruit p300/CBP coactivators, and is a required component of the AETFC complex in t(8;21) AML where it recruits CARM1 to activate enhancer-driven gene expression (PMID:22792348, PMID:18160048, PMID:36215477). LYL1 is essential for LMO2-driven thymocyte self-renewal and T-ALL initiation, establishing it as a non-redundant mediator of leukemogenic transcriptional programs (PMID:23926305, PMID:30700838).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 1989 High

    Identification of LYL1 at a T-ALL translocation breakpoint established it as a new bHLH transcription factor family member, raising the question of its DNA-binding specificity and normal cellular function.

    Evidence Molecular cloning and sequence analysis from t(7;19) T-ALL

    PMID:2752424

    Open questions at the time
    • No binding partners or DNA target specificity determined
    • Normal tissue expression pattern not fully characterized
  2. 1996 High

    Demonstrating that LYL1 heterodimerizes with E2A proteins and binds a distinct DNA consensus sequence resolved how LYL1 achieves target gene specificity distinct from E2A homodimers.

    Evidence Yeast two-hybrid, Co-IP, PCR-assisted binding site selection

    PMID:8628307

    Open questions at the time
    • Endogenous genomic targets not identified
    • Functional consequence of DNA binding on gene expression unknown
  3. 1999 High

    Discovery that LYL1 physically interacts with NF-κB1 p105 and represses NF-κB-dependent transcription revealed a novel bHLH-ankyrin interaction mechanism and a potential link between LYL1 dysregulation and inflammatory/immune signaling.

    Evidence Yeast two-hybrid, in vitro binding, Co-IP, NF-κB reporter assays in T cells

    PMID:10023675

    Open questions at the time
    • Physiological relevance of LYL1-NF-κB interaction in hematopoiesis not tested in vivo
    • Whether this interaction occurs at endogenous protein levels unclear
  4. 2006 High

    Lyl1 knockout mice established that LYL1 is required for HSC self-renewal and B-cell differentiation in vivo, moving it from an oncogene candidate to a physiological regulator of hematopoiesis; parallel promoter analysis revealed GATA-2 and Ets factor regulation of Lyl1 expression, while demonstrating that Lyl1 cannot substitute for Scl in early hematopoietic specification.

    Evidence Lyl1-KO mice with competitive repopulation, transgenic promoter analysis, ChIP, ES cell rescue

    PMID:16514064 PMID:17053063

    Open questions at the time
    • Specific transcriptional targets of LYL1 in HSCs not identified
    • Degree of redundancy with SCL not genetically tested
  5. 2007 High

    Identification of LYL1-CREB1 interaction and p300/CBP coactivator recruitment defined a phosphorylation-independent transcriptional activation mechanism, while overexpression studies showed LYL1 can sequester E2A and promote lymphomagenesis.

    Evidence Co-IP with domain mapping, ChIP-chip, reporter assays; mammalian two-hybrid and transgenic mouse lymphoma model

    PMID:17486074 PMID:18160048

    Open questions at the time
    • Whether LYL1-CREB1 complexes operate in normal hematopoiesis vs. leukemia not distinguished
    • Genome-wide target overlap between LYL1-E2A and LYL1-CREB1 complexes unknown
  6. 2009 High

    Conditional double-knockout of Lyl1 and Scl proved genetic redundancy for adult HSC survival, with a single Lyl1 allele sufficient for rescue, establishing LYL1 as the more potent factor in adult HSC maintenance.

    Evidence Conditional DKO mice, bone marrow repopulation, apoptosis assays

    PMID:19200805

    Open questions at the time
    • Molecular basis for why one Lyl1 allele suffices but one Scl allele does not was not resolved
    • Shared vs. unique chromatin targets not mapped
  7. 2010 High

    Characterization of LYL1 protein turnover revealed PEST-dependent proteasomal degradation independent of MAPK-mediated Ser36 phosphorylation, while in vivo vascular studies established LYL1 as a regulator of blood vessel maturation controlling VE-cadherin, pericyte coverage, and angiopoietin-2.

    Evidence PEST mutagenesis with proteasome inhibitors; Lyl1-KO tumor implantation, Matrigel assay, LYL1 knockdown in endothelial cells

    PMID:20418284 PMID:20844761

    Open questions at the time
    • E3 ubiquitin ligase targeting LYL1 not identified
    • Transcriptional vs. post-transcriptional regulation of vascular targets not fully separated
  8. 2012 High

    A series of studies defined LYL1's multilineage functions: LYL1 occupies the ANG-2 promoter with LMO2/GATA2 in endothelial cells, maintains early T-cell progenitors via Gfi1 activation, supports erythropoiesis by regulating Bcl-xL, and co-regulates STMN1 with CREB1, collectively establishing LYL1 as a versatile bHLH factor with context-dependent target gene programs.

    Evidence ChIP, knockdown, reporter assays in endothelial cells; Lyl1-KO mouse ETP/erythroid phenotyping; ChIP-chip for STMN1 promoter

    PMID:21420467 PMID:22404772 PMID:22792348 PMID:23000483

    Open questions at the time
    • Whether LYL1 activates different gene programs through different partner complexes (E2A vs. CREB1 vs. LMO2) in the same cell type not resolved
    • Full genome-wide target repertoire in primary cells not mapped at this point
  9. 2013 High

    Genetic epistasis demonstrated that LYL1, but not SCL, is essential for LMO2-driven thymocyte self-renewal and T-ALL, establishing a non-redundant oncogenic requirement and explaining why LYL1 is specifically co-expressed with LMO2 in ETP-ALL.

    Evidence Lmo2-Tg × Lyl1-KO vs. Scl-KO mice, serial transplantation, gene expression profiling

    PMID:23926305

    Open questions at the time
    • Direct LYL1-LMO2 binding sites in leukemic thymocytes not mapped by ChIP-seq
    • Whether LYL1 is sufficient or merely required for LMO2 oncogenic activity unknown
  10. 2014 High

    Mechanistic dissection of the vascular barrier phenotype showed LYL1 acts upstream of VE-cadherin and Rap1/RhoA by transcriptionally controlling ARHGAP21 and ARHGAP24, providing a molecular pathway for LYL1's endothelial function.

    Evidence LYL1 knockdown in HUVECs, Lyl1-KO mouse lung permeability (Evans blue), RhoA activity assay, immunofluorescence

    PMID:24532287

    Open questions at the time
    • Whether LYL1 directly binds ARHGAP21/24 promoters not shown by ChIP
    • Contribution of other LYL1 vascular targets to barrier function not assessed
  11. 2018 High

    ChIP-seq in erythroid cells revealed that LYL1 exclusively occupies a subset of SCL targets including the GATA1 locus, and double knockout confirmed that LYL1 maintains primitive erythropoiesis by sustaining GATA1 expression when SCL is absent.

    Evidence Conditional Scl/Lyl1 DKO, ChIP-seq in human erythroleukemia cells, transcriptomics

    PMID:30185409

    Open questions at the time
    • Whether LYL1 binds the same sites in primary erythroid progenitors vs. cell lines not confirmed
    • Structural basis for LYL1 vs. SCL binding site preference unknown
  12. 2019 High

    Studies extended LYL1's non-redundant oncogenic role to NUP98-HOXD13-driven leukemia and confirmed redundancy with SCL in megakaryopoiesis, where both factors regulate Gata1, Fli1, and Nfe2 through shared E-box sites.

    Evidence NHD13-Tg × Lyl1-KO, serial transplantation; Pf4-Cre conditional DKO, platelet assays, ChIP-seq

    PMID:30700838 PMID:31300405

    Open questions at the time
    • Whether LYL1-dependent self-renewal programs are identical across different oncogene contexts not compared
    • Megakaryocyte-specific LYL1 ChIP-seq not performed
  13. 2021 Medium

    Disruption of LYL1's bHLH domain in yolk sac macrophage progenitors revealed a role in primitive macrophage differentiation and microglia production, expanding LYL1 function beyond definitive hematopoiesis to embryonic tissue-resident immune cell development.

    Evidence Lyl1-KO (bHLH disruption), flow cytometry, transcriptomics, immunohistochemistry in embryonic brain

    PMID:34887504

    Open questions at the time
    • Whether residual truncated LYL1 protein retains partial activity not excluded
    • Direct transcriptional targets in macrophage progenitors not identified
  14. 2022 High

    Biochemical purification of the AETFC complex in t(8;21) AML demonstrated that LYL1 is a core subunit required for complex assembly at active enhancers and recruits the coactivator CARM1 to promote AML1-ETO-dependent gene activation, providing a mechanistic basis for LYL1's role in leukemia maintenance.

    Evidence Complex purification, Co-IP, ChIP-seq, gene expression assays in Kasumi-1 cells

    PMID:36215477

    Open questions at the time
    • Whether CARM1 recruitment is specific to AETFC or shared with other LYL1 complexes unknown
    • Therapeutic vulnerability of LYL1 within AETFC not tested
  15. 2024 Medium

    New contexts for LYL1 function emerged: BHLHE40/AR-mediated upregulation of LYL1 in androgen-induced senescence and SPI1/PU.1-dependent regulation of LYL1 during endothelial-to-hematopoietic transition broadened the regulatory network governing and governed by LYL1.

    Evidence ChIP-seq, RNA-seq, Co-IP, siRNA rescue in prostate cancer cells; SPI1-KD/LYL1 rescue in human PSC-derived EHT

    PMID:39108738 PMID:39668349

    Open questions at the time
    • LYL1-BHLHE40-AR complex stoichiometry and genomic targets not fully defined
    • Whether SPI1-LYL1 axis operates in vivo during EHT not confirmed

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the structural basis for LYL1 vs. SCL target selectivity, the identity of the E3 ligase mediating LYL1 proteasomal turnover, genome-wide comparison of LYL1 complex composition across cell types, and whether LYL1 can be therapeutically targeted in LMO2-driven T-ALL or AML1-ETO AML.
  • No structural model of LYL1 or LYL1-containing complexes exists
  • E3 ubiquitin ligase for LYL1 degradation not identified
  • No pharmacological strategy to target LYL1 in leukemia has been tested

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 7 GO:0003677 DNA binding 3
Localization
GO:0005634 nucleus 4
Pathway
R-HSA-74160 Gene expression (Transcription) 6 R-HSA-1266738 Developmental Biology 4 R-HSA-1643685 Disease 3
Partners
BHLHE40CARM1CREB1GATA2LDB1LMO2NFKB1TCF3
Complex memberships
AETFC (AML1-ETO/LYL1/LMO2/LDB1/HEB/E2A/CBFβ)LMO2/GATA2/LYL1/TAL1 enhancer complexLYL1-E2A heterodimer

Evidence

Reading pass · 23 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1989 LYL1 encodes a protein containing a helix-loop-helix (HLH) DNA-binding motif, structurally related to Myc, MyoD, and immunoglobulin enhancer-binding proteins, first identified at a chromosomal translocation breakpoint (t(7;19)) in T-ALL. Molecular cloning, sequence analysis, structural prediction Cell High 2752424
1996 LYL1 forms heterodimeric complexes with E2a proteins (E12 and E47) via their HLH motifs, and these endogenous LYL1-E2a complexes bind a preferred DNA sequence (5'-AACAGATG(T/g)T-3') distinct from the muE2 site recognized by E2a homodimers. Yeast two-hybrid screen, in vitro binding assay, co-immunoprecipitation, PCR-assisted site selection Molecular and cellular biology High 8628307
1999 LYL1 physically interacts with NF-κB1 p105 (the precursor of p50) via the bHLH motif of LYL1 and the ankyrin-like motifs of p105; ectopic LYL1 expression in T cells significantly reduces NF-κB-dependent transcription. Yeast two-hybrid screen, in vitro binding assay, co-immunoprecipitation in mammalian cells, transcription reporter assay Oncogene High 10023675
2006 Lyl1 is required for normal hematopoietic stem cell (HSC) function and B-cell differentiation in vivo; Lyl1-null mice show reduced HSC frequency (LSK, LSK-SP) and severely impaired competitive reconstitution, particularly of B and T lineages. Knockout mouse model, competitive bone marrow reconstitution assay, flow cytometry, colony-forming assays Blood High 16514064
2006 Lyl1 promoter activity in hematopoietic progenitor and endothelial cells is driven by conserved binding sites occupied in vivo by GATA-2 and Ets factors (Fli1, Elf1, Erg, PU.1); despite co-regulation with Scl by the same factors, Lyl1 cannot rescue hematopoietic differentiation in Scl-/- ES cells. Transgenic mouse promoter assay, chromatin immunoprecipitation (ChIP), ES cell differentiation rescue assay Blood High 17053063
2007 LYL1 interacts with CREB1 via the N-terminal domain of LYL1 and the Q2/KID domains of CREB1; these complexes recruit p300/CBP (histone acetyltransferases) independently of CREB1 Ser133 phosphorylation and activate CREB1 target gene promoters including Id1, Id3, cyclin D3, Brca1, Btg2, and Egr1. Co-immunoprecipitation, luciferase reporter assay, ChIP-chip, domain-mapping mutagenesis Biochimica et biophysica acta High 18160048
2007 Excess LYL1 blocks E2A dimerization and inhibits E2A regulatory activity on the CD4 promoter, leading to downregulation of E2A/HEB target genes and lymphomagenesis in transgenic mice. Mammalian two-hybrid assay, luciferase reporter assay, RT-PCR, transgenic mouse model Oncogene Medium 17486074
2009 Lyl1 and Scl show genetic redundancy for adult HSC survival; double conditional knockout mice show rapid loss of hematopoietic progenitors via apoptosis, while a single allele of Lyl1 (but not Scl) can rescue HSC function. Conditional double-knockout mouse model, bone marrow repopulation assays, flow cytometry, apoptosis assays Cell stem cell High 19200805
2010 LYL1 protein is degraded by the proteasome via a PEST sequence motif in its N-terminus; LYL1 is phosphorylated by MAPK at Ser36, but proteasomal degradation occurs in a phosphorylation-independent manner. Cell-based protein degradation assays, PEST motif mutagenesis, proteasome inhibitor treatment, site-directed mutagenesis PloS one Medium 20844761
2010 LYL1 is required for maturation of newly formed blood vessels in adult mice; Lyl1-deficient tumor vessels show enlarged lumens, reduced pericyte coverage, increased permeability, and upregulation of Tal-1/VE-Cadherin and Angiopoietin-2; LYL1 controls expression of molecules involved in vascular stabilization in endothelial cells. Lyl1 knockout mouse tumor implantation model, Matrigel assay, aortic explant assay, hematopoietic reconstitution, LYL1 knockdown in human endothelial cells Blood High 20418284
2012 TAL1, LYL1, and LMO2 directly bind an Ebox-GATA composite element in the ANGIOPOIETIN-2 (ANG-2) promoter in human endothelial cells; LMO2 assembles TAL1-E47, LYL1-LYL1 or LYL1-TAL1 dimers with GATA2 into complexes that activate endogenous ANG-2 expression. Chromatin immunoprecipitation (ChIP), knockdown experiments, transient transfection reporter assay, promoter mutagenesis PloS one High 22792348
2012 Lyl1 is required for lymphoid specification and maintenance of early T lineage progenitors (ETPs); Lyl1 deficiency causes apoptosis and blocked differentiation in ETPs and DN2 thymocytes; Gfi1 was identified as a critical transcriptional target of Lyl1 in T-cell lymphopoiesis. Lyl1 knockout mouse, flow cytometry, apoptosis assays, gene expression profiling, ChIP Nature immunology High 22404772
2012 Lyl1 deficiency results in a stress erythropoiesis phenotype: partial differentiation arrest and enhanced apoptosis with decreased Bcl-xL in bone marrow, compensatory splenic erythropoiesis, and hypersensitivity to erythropoietin in erythroid progenitors. Knockout mouse model, progenitor assays, flow cytometry, competitive reconstitution assay, qRT-PCR Experimental hematology High 21420467
2012 LYL1 and CREB1 co-occupy the STMN1 (Op18/stathmin) promoter in vivo and together co-regulate STMN1 expression; NLI, LMO2, and GATA2 potentiate LYL1-mediated activation of STMN1 promoter, while TAL1 has no effect on this promoter. ChIP-chip, promoter reporter assay, site-directed mutagenesis, shRNA knockdown Biochimica et biophysica acta Medium 23000483
2013 Lyl1 (but not Scl) is required for all oncogenic functions of Lmo2 in T-ALL, including upregulation of a stem cell-like gene signature, aberrant self-renewal of thymocytes, and leukemia generation; LMO2 must recruit LYL1 to DNA to mediate leukemic activity. Transgenic mouse model (Lmo2-Tg × Lyl1-KO or Scl-KO), serial transplantation, gene expression profiling Blood High 23926305
2014 LYL1 is required for endothelial barrier integrity in adult mouse lungs; LYL1 knockdown downregulates ARHGAP21 and ARHGAP24 (Rho GTPase-activating proteins), leading to increased RhoA activity and actin stress fiber formation; Lyl1-deficient mice show impaired VE-cadherin/p120-catenin recruitment to adherens junctions and increased lung vascular permeability; LYL1 acts upstream of VE-cadherin and the GTPases Rap1 and RhoA. LYL1 knockdown in human endothelial cells, Lyl1 knockout mouse, immunofluorescence, Evans blue permeability assay, RhoA activity assay American journal of physiology. Lung cellular and molecular physiology High 24532287
2018 Lyl1 can maintain primitive erythropoiesis in the absence of Scl; LYL1 exclusively binds a subset of SCL targets including GATA1 in erythroid cells, and double knockout of Scl and Lyl1 causes loss of Gata1 and SCL-GATA1 complex target genes, resulting in embryonic lethality from loss of erythropoiesis. Conditional double-knockout mouse, ChIP-seq (human erythroleukemia cell line), gene expression profiling Development High 30185409
2019 Lyl1 is essential for expression of a stem cell-like gene expression program in thymocytes induced by NUP98-HOXD13 and required for thymocyte self-renewal; Lmo2-mediated thymocyte self-renewal also requires Lyl1. NHD13-transgenic × Lyl1-knockout mouse, serial transplantation, transcriptome analysis Leukemia High 30700838
2019 Scl and Lyl1 share functional roles in platelet production by redundantly regulating expression of partner transcription factors Gata1, Fli1, Nfe2, and others via shared E-box binding sites enriched for Gata1, Ets, and Runx1 motifs in megakaryocytes. Conditional double-knockout mouse (Pf4-Cre), platelet aggregation assay, gene expression analysis, ChIP-seq E-box binding site analysis Blood High 31300405
2021 Lyl-1 disruption in yolk sac macrophage progenitors (via disruption of its bHLH domain) leads to increased emergence but defective differentiation of primitive macrophage progenitors and reduced microglia production in the brain, with associated disruption of embryonic patterning and neurodevelopment gene sets. Lyl1 knockout mouse (bHLH domain disruption), transcriptomic analysis, flow cytometry, immunohistochemistry Communications biology Medium 34887504
2022 LYL1 is required for assembly of the larger AETFC complex (containing AML1-ETO, CBFβ, HEB, E2A, LYL1, LMO2, LDB1) in t(8;21) AML; LYL1-containing AETFC preferentially binds active enhancers; LYL1 recruits coactivator CARM1 to chromatin to promote AE-dependent gene activation. Biochemical complex purification, co-immunoprecipitation, ChIP-seq, genomic binding analysis, functional gene expression assays Proceedings of the National Academy of Sciences of the United States of America High 36215477
2024 LYL1 expression is upregulated by BHLHE40 in response to supraphysiological androgen; LYL1 forms a complex with BHLHE40 and the androgen receptor (AR); LYL1 mediates SAL-induced cellular senescence partly through regulation of p27kip1; AR and BHLHE40 are recruited to the LYL1 gene locus. ChIP-seq, RNA-seq, co-immunoprecipitation, siRNA knockdown, rescue experiments, qRT-PCR Cell communication and signaling Medium 39668349
2024 SPI1 (PU.1) regulates LYL1 as a downstream transcriptional target during endothelial-to-hematopoietic transition; LYL1 overexpression rescues the lymphoid lineage potential lost upon SPI1 knockdown. SPI1 knockdown, LYL1 overexpression rescue, multi-omic analysis of human pluripotent stem cell-derived EHT iScience Medium 39108738

Source papers

Stage 0 corpus · 40 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1989 lyl-1, a novel gene altered by chromosomal translocation in T cell leukemia, codes for a protein with a helix-loop-helix DNA binding motif. Cell 342 2752424
1993 TAL1, TAL2 and LYL1: a family of basic helix-loop-helix proteins implicated in T cell acute leukaemia. Seminars in cancer biology 117 8142619
2009 Adult hematopoietic stem and progenitor cells require either Lyl1 or Scl for survival. Cell stem cell 111 19200805
2006 The SCL relative LYL-1 is required for fetal and adult hematopoietic stem cell function and B-cell differentiation. Blood 70 16514064
2006 The paralogous hematopoietic regulators Lyl1 and Scl are coregulated by Ets and GATA factors, but Lyl1 cannot rescue the early Scl-/- phenotype. Blood 67 17053063
2013 Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL. Blood 58 23926305
1996 Helix-loop-helix proteins LYL1 and E2a form heterodimeric complexes with distinctive DNA-binding properties in hematolymphoid cells. Molecular and cellular biology 50 8628307
2012 The transcription factor Lyl-1 regulates lymphoid specification and the maintenance of early T lineage progenitors. Nature immunology 49 22772404
1991 Structure, chromosome mapping, and expression of the mouse Lyl-1 gene. Oncogene 48 2067848
2007 Overexpression of a transcription factor LYL1 induces T- and B-cell lymphoma in mice. Oncogene 37 17486074
1999 Physical interaction of the bHLH LYL1 protein and NF-kappaB1 p105. Oncogene 33 10023675
2003 Comparative and functional analyses of LYL1 loci establish marsupial sequences as a model for phylogenetic footprinting. Genomics 31 12659809
2005 Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia. Leukemia 30 16094422
2011 Characterization of a pediatric T-cell acute lymphoblastic leukemia patient with simultaneous LYL1 and LMO2 rearrangements. Haematologica 29 22058201
2009 Multiple mechanisms induce ectopic expression of LYL1 in subsets of T-ALL cell lines. Leukemia research 25 19608273
2006 lyl-1 and tal-1/scl, two genes encoding closely related bHLH transcription factors, display highly overlapping expression patterns during cardiovascular and hematopoietic ontogeny. Gene expression patterns : GEP 25 17112790
2007 Lyl1 interacts with CREB1 and alters expression of CREB1 target genes. Biochimica et biophysica acta 23 18160048
2012 Angiopoietin-2 is a direct transcriptional target of TAL1, LYL1 and LMO2 in endothelial cells. PloS one 22 22792348
2022 Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia. Journal of experimental & clinical cancer research : CR 21 35842703
2022 BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia. Journal of immunology research 16 35958877
2011 LYL-1 deficiency induces a stress erythropoiesis. Experimental hematology 15 21420467
2010 LYL1 activity is required for the maturation of newly formed blood vessels in adulthood. Blood 15 20418284
2014 Lung endothelial barrier disruption in Lyl1-deficient mice. American journal of physiology. Lung cellular and molecular physiology 14 24532287
2019 The NUP98-HOXD13 fusion oncogene induces thymocyte self-renewal via Lmo2/Lyl1. Leukemia 12 30700838
2019 Shared roles for Scl and Lyl1 in murine platelet production and function. Blood 12 31300405
2022 LYL1 facilitates AETFC assembly and gene activation by recruiting CARM1 in t(8;21) AML. Proceedings of the National Academy of Sciences of the United States of America 11 36215477
2021 Lyl-1 regulates primitive macrophages and microglia development. Communications biology 10 34887504
2018 A novel role for Lyl1 in primitive erythropoiesis. Development (Cambridge, England) 10 30185409
2011 A new allele of Lyl1 confirms its important role in hematopoietic stem cell function. Genesis (New York, N.Y. : 2000) 7 21387538
2010 LYL1 degradation by the proteasome is directed by a N-terminal PEST rich site in a phosphorylation-independent manner. PloS one 7 20844761
2024 SPI1-KLF1/LYL1 axis regulates lineage commitment during endothelial-to-hematopoietic transition from human pluripotent stem cells. iScience 6 39108738
2012 Suspected leukemia oncoproteins CREB1 and LYL1 regulate Op18/STMN1 expression. Biochimica et biophysica acta 6 23000483
2010 The expansion of T-cells and hematopoietic progenitors as a result of overexpression of the lymphoblastic leukemia gene, Lyl1 can support leukemia formation. Leukemia research 6 20705338
2024 Functional circuits of LYL1 controlled by supraphysiological androgen in prostate cancer cells to regulate cell senescence. Cell communication and signaling : CCS 4 39668349
2020 In Lyl1-/- mice, adipose stem cell vascular niche impairment leads to premature development of fat tissues. Stem cells (Dayton, Ohio) 3 33022858
2022 Lyl1-deficiency promotes inflammatory responses and increases mycobacterial burden in response to Mycobacterium tuberculosis infection in mice. Frontiers in immunology 1 36119114
2009 [Abnormal expression of transcription factors LYL1 and LMO2 and interaction between them in myeloid leukemia]. Zhonghua yi xue za zhi 1 19671288
2008 [Expression of transcription factor LYL1 in leukemia and its possible role in leukemogenesis]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 1 19176012
2025 Role of different Lyl1 transcripts in zebrafish primitive hematopoiesis. Yi chuan = Hereditas 0 40287790
2024 Multiple primary tumors in a patient with non‑small‑cell lung cancer harboring mutations in ERCC6 and LYL1: A case report. Oncology letters 0 39611066